Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Belynda Hicks is active.

Publication


Featured researches published by Belynda Hicks.


Nature Biotechnology | 2014

Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study.

Sheng Li; Scott Tighe; Charles M. Nicolet; Deborah S. Grove; Shawn Levy; William G. Farmerie; Agnes Viale; Chris L. Wright; Peter A. Schweitzer; Yuan Gao; Dewey Kim; Joe Boland; Belynda Hicks; Ryan Kim; Sagar Chhangawala; Nadereh Jafari; Nalini Raghavachari; Jorge Gandara; Natàlia Garcia-Reyero; Cynthia Hendrickson; David Roberson; Jeffrey Rosenfeld; Todd Smith; Jason G. Underwood; May Wang; Paul Zumbo; Don Baldwin; George Grills; Christopher E. Mason

High-throughput RNA sequencing (RNA-seq) greatly expands the potential for genomics discoveries, but the wide variety of platforms, protocols and performance capabilitites has created the need for comprehensive reference data. Here we describe the Association of Biomolecular Resource Facilities next-generation sequencing (ABRF-NGS) study on RNA-seq. We carried out replicate experiments across 15 laboratory sites using reference RNA standards to test four protocols (poly-A–selected, ribo-depleted, size-selected and degraded) on five sequencing platforms (Illumina HiSeq, Life Technologies PGM and Proton, Pacific Biosciences RS and Roche 454). The results show high intraplatform (Spearman rank R > 0.86) and inter-platform (R > 0.83) concordance for expression measures across the deep-count platforms, but highly variable efficiency and cost for splice junction and variant detection between all platforms. For intact RNA, gene expression profiles from rRNA-depletion and poly-A enrichment are similar. In addition, rRNA depletion enables effective analysis of degraded RNA samples. This study provides a broad foundation for cross-platform standardization, evaluation and improvement of RNA-seq.


BMC Genomics | 2009

High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays

Jun Wang; Min Lin; Andrew Crenshaw; Amy Hutchinson; Belynda Hicks; Meredith Yeager; Sonja I. Berndt; Wen-Yi Huang; Richard B. Hayes; Stephen J. Chanock; Robert C. Jones; Ramesh Ramakrishnan

BackgroundSingle nucleotide polymorphisms (SNPs) have emerged as the genetic marker of choice for mapping disease loci and candidate gene association studies, because of their high density and relatively even distribution in the human genomes. There is a need for systems allowing medium multiplexing (ten to hundreds of SNPs) with high throughput, which can efficiently and cost-effectively generate genotypes for a very large sample set (thousands of individuals). Methods that are flexible, fast, accurate and cost-effective are urgently needed. This is also important for those who work on high throughput genotyping in non-model systems where off-the-shelf assays are not available and a flexible platform is needed.ResultsWe demonstrate the use of a nanofluidic Integrated Fluidic Circuit (IFC) - based genotyping system for medium-throughput multiplexing known as the Dynamic Array, by genotyping 994 individual human DNA samples on 47 different SNP assays, using nanoliter volumes of reagents. Call rates of greater than 99.5% and call accuracies of greater than 99.8% were achieved from our study, which demonstrates that this is a formidable genotyping platform. The experimental set up is very simple, with a time-to-result for each sample of about 3 hours.ConclusionOur results demonstrate that the Dynamic Array is an excellent genotyping system for medium-throughput multiplexing (30-300 SNPs), which is simple to use and combines rapid throughput with excellent call rates, high concordance and low cost. The exceptional call rates and call accuracy obtained may be of particular interest to those working on validation and replication of genome- wide- association (GWA) studies.


Genes & Development | 2014

Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1

Hande Kocak; Bari J. Ballew; Kamlesh Bisht; Rebecca Eggebeen; Belynda Hicks; Shalabh Suman; Adri O’Neil; Neelam Giri; Ivan Maillard; Blanche P. Alter; Catherine E. Keegan; Jayakrishnan Nandakumar; Sharon A. Savage

Germline mutations in telomere biology genes cause dyskeratosis congenita (DC), an inherited bone marrow failure and cancer predisposition syndrome. DC is a clinically heterogeneous disorder diagnosed by the triad of dysplastic nails, abnormal skin pigmentation, and oral leukoplakia; Hoyeraal-Hreidarsson syndrome (HH), a clinically severe variant of DC, also includes cerebellar hypoplasia, immunodeficiency, and intrauterine growth retardation. Approximately 70% of DC cases are associated with a germline mutation in one of nine genes, the products of which are all involved in telomere biology. Using exome sequencing, we identified mutations in Adrenocortical Dysplasia Homolog (ACD) (encoding TPP1), a component of the telomeric shelterin complex, in one family affected by HH. The proband inherited a deletion from his father and a missense mutation from his mother, resulting in extremely short telomeres and a severe clinical phenotype. Characterization of the mutations revealed that the single-amino-acid deletion affecting the TEL patch surface of the TPP1 protein significantly compromises both telomerase recruitment and processivity, while the missense mutation in the TIN2-binding region of TPP1 is not as clearly deleterious to TPP1 function. Our results emphasize the critical roles of the TEL patch in proper stem cell function and demonstrate that TPP1 is the second shelterin component (in addition to TIN2) to be implicated in DC.


Cancer Epidemiology, Biomarkers & Prevention | 2017

The OncoArray Consortium: a Network for Understanding the Genetic Architecture of Common Cancers.

Christopher I. Amos; Joe Dennis; Zhaoming Wang; Jinyoung Byun; Fredrick R. Schumacher; Simon A. Gayther; Graham Casey; David J. Hunter; Thomas A. Sellers; Stephen B. Gruber; Alison M. Dunning; Kyriaki Michailidou; Laura Fachal; Kimberly F. Doheny; Amanda B. Spurdle; Yafang Li; Xiangjun Xiao; Jane Romm; Elizabeth W. Pugh; Gerhard A. Coetzee; Dennis J. Hazelett; Stig E. Bojesen; Charlisse F. Caga-anan; Christopher A. Haiman; Ahsan Kamal; Craig Luccarini; Daniel C. Tessier; Daniel Vincent; Francois Bacot; David Van Den Berg

Background: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. Methods: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. Results: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. Conclusions: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. Impact: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126–35. ©2016 AACR.


Blood | 2014

Whole-exome sequencing and functional studies identify RPS29 as a novel gene mutated in multicase Diamond-Blackfan anemia families

Lisa Mirabello; Elizabeth R. Macari; Lea Jessop; Steven R. Ellis; Timothy G. Myers; Neelam Giri; Alison M. Taylor; Katherine E. McGrath; Jessica M. Humphries; Bari J. Ballew; Meredith Yeager; Joseph F. Boland; Ji He; Belynda Hicks; Laurie Burdett; Blanche P. Alter; Leonard I. Zon; Sharon A. Savage

Diamond-Blackfan anemia (DBA) is a cancer-prone inherited bone marrow failure syndrome. Approximately half of DBA patients have a germ-line mutation in a ribosomal protein gene. We used whole-exome sequencing to identify disease-causing genes in 2 large DBA families. After filtering, 1 nonsynonymous mutation (p.I31F) in the ribosomal protein S29 (RPS29[AUQ1]) gene was present in all 5 DBA-affected individuals and the obligate carrier, and absent from the unaffected noncarrier parent in 1 DBA family. A second DBA family was found to have a different nonsynonymous mutation (p.I50T) in RPS29. Both mutations are amino acid substitutions in exon 2 predicted to be deleterious and resulted in haploinsufficiency of RPS29 expression compared with wild-type RPS29 expression from an unaffected control. The DBA proband with the p.I31F RPS29 mutation had a pre-ribosomal RNA (rRNA) processing defect compared with the healthy control. We demonstrated that both RPS29 mutations failed to rescue the defective erythropoiesis in the rps29(-/-) mutant zebra fish DBA model. RPS29 is a component of the small 40S ribosomal subunit and essential for rRNA processing and ribosome biogenesis. We uncovered a novel DBA causative gene, RPS29, and showed that germ-line mutations in RPS29 can cause a defective erythropoiesis phenotype using a zebra fish model.


Cancer Discovery | 2015

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

Lisa Mirabello; Roelof Koster; Branden S. Moriarity; Logan G. Spector; Paul S. Meltzer; Joy Gary; Mitchell J. Machiela; Nathan Pankratz; Orestis A. Panagiotou; David A. Largaespada; Zhaoming Wang; Julie M. Gastier-Foster; Richard Gorlick; Chand Khanna; Silvia Regina Caminada de Toledo; Antonio Sergio Petrilli; Ana Patiño-García; Luis Sierrasesúmaga; Fernando Lecanda; Irene L. Andrulis; Jay S. Wunder; Nalan Gokgoz; Massimo Serra; Claudia M. Hattinger; Piero Picci; Katia Scotlandi; Adrienne M. Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Dina Halai

UNLABELLED Metastasis is the leading cause of death in patients with osteosarcoma, the most common pediatric bone malignancy. We conducted a multistage genome-wide association study of osteosarcoma metastasis at diagnosis in 935 osteosarcoma patients to determine whether germline genetic variation contributes to risk of metastasis. We identified an SNP, rs7034162, in NFIB significantly associated with metastasis in European osteosarcoma cases, as well as in cases of African and Brazilian ancestry (meta-analysis of all cases: P = 1.2 × 10(-9); OR, 2.43; 95% confidence interval, 1.83-3.24). The risk allele was significantly associated with lowered NFIB expression, which led to increased osteosarcoma cell migration, proliferation, and colony formation. In addition, a transposon screen in mice identified a significant proportion of osteosarcomas harboring inactivating insertions in Nfib and with lowered NFIB expression. These data suggest that germline genetic variation at rs7034162 is important in osteosarcoma metastasis and that NFIB is an osteosarcoma metastasis susceptibility gene. SIGNIFICANCE Metastasis at diagnosis in osteosarcoma is the leading cause of death in these patients. Here we show data that are supportive for the NFIB locus as associated with metastatic potential in osteosarcoma.


Science | 2017

Loci associated with skin pigmentation identified in African populations

Nicholas G. Crawford; Derek Kelly; Matthew Hansen; Marcia Holsbach Beltrame; Shaohua Fan; Shanna L. Bowman; Ethan M. Jewett; Alessia Ranciaro; Simon Thompson; Yancy Lo; Susanne P. Pfeifer; Jeffrey D. Jensen; Michael C. Campbell; William Beggs; Farhad Hormozdiari; Sununguko W. Mpoloka; Gaonyadiwe George Mokone; Thomas B. Nyambo; Dawit Wolde Meskel; Gurja Belay; Jake Haut; Harriet Rothschild; Leonard I. Zon; Yi Zhou; Michael Kovacs; Mai Xu; Tongwu Zhang; Kevin Bishop; Jason Sinclair; Cecilia Rivas

African genomics and skin color Skin color varies among human populations and is thought to be under selection, with light skin maximizing vitamin D production at higher latitudes and dark skin providing UV protection in equatorial zones. To identify the genes that give rise to the palette of human skin tones, Crawford et al. applied genome-wide analyses across diverse African populations (see the Perspective by Tang and Barsh). Genetic variants were identified with likely function in skin phenotypes. Comparison to model organisms verified a conserved function of MFSD12 in pigmentation. A global genetic panel was used to trace how alleles associated with skin color likely moved across the globe as humans migrated, both within and out of Africa. Science, this issue p. eaan8433; see also p. 867 Genome-wide analysis of 2000 Africans identifies and functionally characterizes pigmentation loci. INTRODUCTION Variation in pigmentation among human populations may reflect local adaptation to regional light environments, because dark skin is more photoprotective, whereas pale skin aids the production of vitamin D. Although genes associated with skin pigmentation have been identified in European populations, little is known about the genetic basis of skin pigmentation in Africans. RATIONALE Genetically and phenotypically diverse African populations are informative for mapping genetic variants associated with skin pigmentation. Analysis of the genetics of skin pigmentation in Africans informs upon melanocyte biology and the evolution of skin pigmentation in humans. RESULTS We observe extensive variation in skin pigmentation in Africa, with lowest melanin levels observed in southern African San hunter-gatherers and highest levels in East African Nilo-Saharan pastoralists. A genome-wide association study (GWAS) of 1570 Africans identified variants significantly associated with skin pigmentation, which clustered in four genomic regions that together account for almost 30% of the phenotypic variation. The most significantly associated single-nucleotide polymorphisms were at SLC24A5, a gene associated with pigmentation in Europeans. We show that SLC24A5 was introduced into East Africa >5 thousand years ago (ka) and has risen to high frequency. The second most significantly associated region is near the gene MFSD12. Using in vitro and in vivo analyses, we show that MFSD12 codes for a lysosomal protein that modifies pigmentation in human melanocytes, with decreased MFSD12 expression associated with darker pigmentation. We also show that genetic knockout of Mfsd12 affects pigmentation in mice. A third highly associated region encompasses a cluster of genes that play a role in ultraviolet (UV) response and DNA damage repair. We find the strongest associations in a regulatory region upstream of DDB1, the gene encoding damage-specific DNA binding protein 1, and that these variants are associated with increased expression of DDB1. The alleles associated with light pigmentation swept to near fixation outside of Africa due to positive selection, and we show that these lineages coalesce ~60 ka, corresponding with the time of migration of modern humans out of Africa. The fourth significantly associated region encompasses the OCA2 and HERC2 loci. We identify previously uncharacterized variants at HERC2 associated with the expression of OCA2. These variants arose independently from eye and skin pigmentation–associated variants in non-Africans. We also identify variants at OCA2 that are correlated with alternative splicing; alleles associated with light pigmentation are correlated with a shorter transcript, which lacks a transmembrane domain. CONCLUSION We identify previously uncharacterized genes and variants associated with skin pigmentation in ethnically diverse Africans. These genes have diverse functions, from repairing UV damage to playing important roles in melanocyte biology. We show that both dark and light pigmentation alleles arose before the origin of modern humans and that both light and dark pigmented skin has continued to evolve throughout hominid history. We show that variants associated with dark pigmentation in Africans are identical by descent in South Asian and Australo-Melanesian populations. This study sheds light on the evolutionary history, and adaptive significance, of skin pigmentation in humans. GWAS and functional assays illuminate the genetic basis of pigmentation in Africa. A GWAS identified four genomic regions associated with skin pigmentation in Africa. Functional assays in melanocytes and mice characterized their impact on skin pigmentation. Evolutionary genetic analyses revealed that most derived variants evolved before the origin of modern humans. Ma, million years ago. Despite the wide range of skin pigmentation in humans, little is known about its genetic basis in global populations. Examining ethnically diverse African genomes, we identify variants in or near SLC24A5, MFSD12, DDB1, TMEM138, OCA2, and HERC2 that are significantly associated with skin pigmentation. Genetic evidence indicates that the light pigmentation variant at SLC24A5 was introduced into East Africa by gene flow from non-Africans. At all other loci, variants associated with dark pigmentation in Africans are identical by descent in South Asian and Australo-Melanesian populations. Functional analyses indicate that MFSD12 encodes a lysosomal protein that affects melanogenesis in mice, and that mutations in melanocyte-specific regulatory regions near DDB1/TMEM138 correlate with expression of ultraviolet response genes under selection in Eurasians.


Journal of Medical Genetics | 2017

Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation

Lisa Mirabello; Payal P. Khincha; Steven R. Ellis; Neelam Giri; Seth Brodie; Settara C. Chandrasekharappa; Frank X. Donovan; Weiyin Zhou; Belynda Hicks; Joseph Boland; Meredith Yeager; Bin Zhu; Mingyi Wang; Blanche P. Alter; Sharon A. Savage

Background Diamond-Blackfan anaemia (DBA) is an inherited bone marrow failure syndrome (IBMFS) characterised by erythroid hypoplasia. It is associated with congenital anomalies and a high risk of developing specific cancers. DBA is caused predominantly by autosomal dominant pathogenic variants in at least 15 genes affecting ribosomal biogenesis and function. Two X-linked recessive genes have been identified. Objectives We aim to identify the genetic aetiology of DBA. Methods Of 87 families with DBA enrolled in an institutional review board-approved cohort study (ClinicalTrials.gov Identifier:NCT00027274), 61 had genetic testing information available. Thirty-five families did not have a known genetic cause and thus underwent comprehensive genomic evaluation with whole exome sequencing, deletion and CNV analyses to identify their disease-associated pathogenic variant. Controls for functional studies were healthy mutation-negative individuals enrolled in the same study. Results Our analyses uncovered heterozygous pathogenic variants in two previously undescribed genes in two families. One family had a non-synonymous variant (p.K77N) in RPL35; the second family had a non-synonymous variant (p. L51S) in RPL18. Both of these variants result in pre-rRNA processing defects. We identified heterozygous pathogenic variants in previously known DBA genes in 16 of 35 families. Seventeen families who underwent genetic analyses are yet to have a genetic cause of disease identified. Conclusions Overall, heterozygous pathogenic variants in ribosomal genes were identified in 44 of the 61 families (72%). De novo pathogenic variants were observed in 57% of patients with DBA. Ongoing studies of DBA genomics will be important to understand this complex disorder.


Haematologica | 2016

Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene

Melissa Rotunno; Mary L. McMaster; Joseph Boland; Sara Bass; Xijun Zhang; Laurie Burdett; Belynda Hicks; Sarangan Ravichandran; Brian T. Luke; Meredith Yeager; Laura Fontaine; Paula L. Hyland; Alisa M. Goldstein; Stephen J. Chanock; Neil E. Caporaso; Margaret A. Tucker; Lynn R. Goldin

Hodgkin lymphoma shows strong familial aggregation but no major susceptibility genes have been identified to date. The goal of this study was to identify high-penetrance variants using whole exome sequencing in 17 Hodgkin lymphoma prone families with three or more affected cases or obligate carriers (69 individuals), followed by targeted sequencing in an additional 48 smaller HL families (80 individuals). Alignment and variant calling were performed using standard methods. Dominantly segregating, rare, coding or potentially functional variants were further prioritized based on predicted deleteriousness, conservation, and potential importance in lymphoid malignancy pathways. We selected 23 genes for targeted sequencing. Only the p.A1065T variant in KDR (kinase insert domain receptor) also known as VEGFR2 (vascular endothelial growth factor receptor 2) was replicated in two independent Hodgkin lymphoma families. KDR is a type III receptor tyrosine kinase, the main mediator of vascular endothelial growth factor induced proliferation, survival, and migration. Its activity is associated with several diseases including lymphoma. Functional experiments have shown that p.A1065T, located in the activation loop, can promote constitutive autophosphorylation on tyrosine in the absence of vascular endothelial growth factor and that the kinase activity was abrogated after exposure to kinase inhibitors. A few other promising mutations were identified but appear to be “private”. In conclusion, in the largest sequenced cohort of Hodgkin lymphoma families to date, we identified a causal mutation in the KDR gene. While independent validation is needed, this mutation may increase downstream tumor cell proliferation activity and might be a candidate for targeted therapy.


PLOS Medicine | 2016

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Jianxin Shi; Xing Hua; Bin Zhu; Sarangan Ravichandran; Mingyi Wang; Cu Nguyen; Seth Brodie; Alessandro Palleschi; Marco Alloisio; Gianluca Pariscenti; Weiyin Zhou; Aaron J. Bouk; Joseph Boland; Belynda Hicks; Adam Risch; Hunter Bennett; Brian T. Luke; Lei Song; Jubao Duan; Pengyuan Liu; Takashi Kohno; Qing-Rong Chen; Daoud Meerzaman; Crystal N. Marconett; Ite A. Laird-Offringa; Ian W. Mills; Neil E. Caporaso; Mitchell H. Gail; Angela C. Pesatori; Dario Consonni

Background Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk of distant metastasis at every disease stage. We aimed to characterize the genomic landscape of LUAD and identify mutation signatures associated with tumor progression. Methods and Findings We performed an integrative genomic analysis, incorporating whole exome sequencing (WES), determination of DNA copy number and DNA methylation, and transcriptome sequencing for 101 LUAD samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. We detected driver genes by testing whether the nonsynonymous mutation rate was significantly higher than the background mutation rate and replicated our findings in public datasets with 724 samples. We performed subclonality analysis for mutations based on mutant allele data and copy number alteration data. We also tested the association between mutation signatures and clinical outcomes, including distant metastasis, survival, and tumor grade. We identified and replicated two novel candidate driver genes, POU class 4 homeobox 2 (POU4F2) (mutated in 9 [8.9%] samples) and ZKSCAN1 (mutated in 6 [5.9%] samples), and characterized their major deleterious mutations. ZKSCAN1 was part of a mutually exclusive gene set that included the RTK/RAS/RAF pathway genes BRAF, EGFR, KRAS, MET, and NF1, indicating an important driver role for this gene. Moreover, we observed strong associations between methylation in specific genomic regions and somatic mutation patterns. In the tumor evolution analysis, four driver genes had a significantly lower fraction of subclonal mutations (FSM), including TP53 (p = 0.007), KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR (p = 0.0078), suggesting a tumor initiation role for these genes. Subclonal mutations were significantly enriched in APOBEC-related signatures (p < 2.5×10−50). The total number of somatic mutations (p = 0.0039) and the fraction of transitions (p = 5.5×10−4) were associated with increased risk of distant metastasis. Our study’s limitations include a small number of LUAD patients for subgroup analyses and a single-sample design for investigation of subclonality. Conclusions These data provide a genomic characterization of LUAD pathogenesis and progression. The distinct clonal and subclonal mutation signatures suggest possible diverse carcinogenesis pathways for endogenous and exogenous exposures, and may serve as a foundation for more effective treatments for this lethal disease. LUAD’s high heterogeneity emphasizes the need to further study this tumor type and to associate genomic findings with clinical outcomes.

Collaboration


Dive into the Belynda Hicks's collaboration.

Top Co-Authors

Avatar

Meredith Yeager

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Bin Zhu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sharon A. Savage

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Stephen J. Chanock

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Amy Hutchinson

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Margaret A. Tucker

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Blanche P. Alter

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jianxin Shi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph Boland

Science Applications International Corporation

View shared research outputs
Researchain Logo
Decentralizing Knowledge